β-Adrenergic Receptor–Mediated Cardiac Contractility Is Inhibited via Vasopressin Type 1A-Receptor–Dependent Signaling | Zendy

Douglas G. Tilley | Zendy; Weizhong Zhu | Zendy; Valerie D. Myers | Zendy; Larry A. Barr | Zendy; Erhe Gao | Zendy; Xue Li | Zendy; Jianliang Song | Zendy; Rhonda L. Carter | Zendy; Catherine A. Makarewich | Zendy; Daohai Yu | Zendy; Constantine D. Troupes | Zendy; Laurel A. Grisanti | Zendy; Ryan C. Coleman | Zendy; Walter J. Koch | Zendy; Steven R. Houser | Zendy; Joseph Y. Cheung | Zendy; Arthur M. Feldman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

β-Adrenergic Receptor–Mediated Cardiac Contractility Is Inhibited via Vasopressin Type 1A-Receptor–Dependent Signaling

Author(s) -

Douglas G. Tilley,

Weizhong Zhu,

Valerie D. Myers,

Larry A. Barr,

Erhe Gao,

Xue Li,

Jianliang Song,

Rhonda L. Carter,

Catherine A. Makarewich,

Daohai Yu,

Constantine D. Troupes,

Laurel A. Grisanti,

Ryan C. Coleman,

Walter J. Koch,

Steven R. Houser,

Joseph Y. Cheung,

Arthur M. Feldman

Publication year - 2014

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.114.010434

Subject(s) - medicine , heart failure , endocrinology , vasopressin , contractility , receptor , cardiac function curve , cardiomyopathy , receptor antagonist , g protein coupled receptor kinase , vasopressin receptor , antagonist , g protein

Enhanced arginine vasopressin levels are associated with increased mortality during end-stage human heart failure, and cardiac arginine vasopressin type 1A receptor (V1AR) expression becomes increased. Additionally, mice with cardiac-restricted V1AR overexpression develop cardiomyopathy and decreased β-adrenergic receptor (βAR) responsiveness. This led us to hypothesize that V1AR signaling regulates βAR responsiveness and in doing so contributes to development of heart failure.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research